JACC Adv. 2026 Jan 21;5(2):102552. doi: 10.1016/j.jacadv.2025.102552. Online ahead of print.ABSTRACTBACKGROUND: Data on the contemporary prevalence of hypertrophic cardiomyopathy (HCM) in the United States are limited, and information on the epidemiology by disease characteristics and patient demogr
Eur Heart J Cardiovasc Imaging. 2026 Jan 22:jeag019. doi: 10.1093/ehjci/jeag019. Online ahead of print.ABSTRACTBACKGROUND: Assessing cardiac function is critical for managing cardiovascular disease, guiding treatment, monitoring progression, and risk stratification. While left ventricular ejection f
Asian Cardiovasc Thorac Ann. 2026 Jan 22:2184923261416148. doi: 10.1177/02184923261416148. Online ahead of print.ABSTRACTObstructive hypertrophic cardiomyopathy (oHCM) presents a significant clinical challenge, with left ventricular outflow tract obstruction being a primary driver of symptoms and ad
Eur J Radiol Open. 2026 Jan 8;16:100726. doi: 10.1016/j.ejro.2026.100726. eCollection 2026 Jun.ABSTRACTPURPOSE: This study aimed to explore myocardial transit time (MyoTT) by cardiovascular magnetic resonance (CMR) as a potential parameter of coronary microvascular dysfunction (CMD) in hypertrophic
Clin Case Rep. 2026 Jan 20;14(1):e71908. doi: 10.1002/ccr3.71908. eCollection 2026 Jan.ABSTRACTThe RBM20 gene, located on chromosome 10q25.2, encodes a serine/arginine-rich protein essential for post-transcriptional splicing of several cardiac genes, including titin. Pathogenic variants in RBM20 are
J Int Med Res. 2026 Jan;54(1):3000605251412623. doi: 10.1177/03000605251412623. Epub 2026 Jan 21.ABSTRACTObjectiveTo evaluate the association between the uric acid-to-albumin ratio and adverse clinical outcomes in patients with hypertrophic cardiomyopathy.MethodsThis retrospective, observational sin
Heart Vessels. 2026 Jan 21. doi: 10.1007/s00380-025-02651-2. Online ahead of print.ABSTRACTIn Japan, median waiting time of heart transplantation (HT) is estimated as more than 5 years. Internationally, they report relatively high incidence of right heart failure (RHF) during left ventricular assist
Open Heart. 2026 Jan 21;13(1):e003838. doi: 10.1136/openhrt-2025-003838.ABSTRACTINTRODUCTION: Inherited cardiac conditions, including dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), may have a monogenic cause identified through genetic testing (GT). Confirmation of pathogenic gen
J Cardiovasc Magn Reson. 2026 Jan 19:102695. doi: 10.1016/j.jocmr.2026.102695. Online ahead of print.ABSTRACT"Cases of SCMR" is a case series on the SCMR website (https://www.scmr.org) for the purpose of education. The cases reflect the clinical presentation, and the use of cardiovascular magnetic r
JACC Adv. 2026 Jan 20;5(2):102563. doi: 10.1016/j.jacadv.2025.102563. Online ahead of print.ABSTRACTBACKGROUND: In symptomatic patients with hypertrophic cardiomyopathy (HCM), eliciting left ventricular outflow tract obstruction (LVOTO) is critical. A self-directed Valsalva (SDV) and exercise (EX) a
Pediatr Cardiol. 2026 Jan 21. doi: 10.1007/s00246-025-04151-6. Online ahead of print.ABSTRACTHypertrophic cardiomyopathy (HCM) is the most common genetic heart disease in children and is associated with arrhythmia, heart failure, and sudden cardiac death. Early detection of myocardial dysfunction an
JACC Case Rep. 2025 Dec 31:106609. doi: 10.1016/j.jaccas.2025.106609. Online ahead of print.ABSTRACTBACKGROUND: Hypertrophic cardiomyopathy (HCM) and infiltrative cardiomyopathies are important causes of cardiogenic syncope with overlapping clinical and radiologic features.CASE SUMMARY: A 49-year-ol
No abstractJ Am Coll Cardiol. 2026 Jan 14:S0735-1097(25)10359-8. doi: 10.1016/j.jacc.2025.11.051. Online ahead of print.NO ABSTRACTPMID:41563177 | DOI:10.1016/j.jacc.2025.11.051
Front Cardiovasc Med. 2026 Jan 5;12:1652963. doi: 10.3389/fcvm.2025.1652963. eCollection 2025.ABSTRACTPURPOSE: This study aimed to evaluate the knowledge, attitudes, and behaviors of patients with hypertrophic cardiomyopathy during the rehabilitation process and to explore the variables that influen
Front Cardiovasc Med. 2026 Jan 5;12:1630263. doi: 10.3389/fcvm.2025.1630263. eCollection 2025.ABSTRACTHypertrophic cardiomyopathy (HCM) represents the most prevalent form of hereditary cardiomyopathy, and mutation in the cardiac myosin-binding protein C (MYBPC3) gene have been identified as a major
Medicine (Baltimore). 2026 Jan 16;105(3):e46993. doi: 10.1097/MD.0000000000046993.ABSTRACTRATIONALE: Danon disease (DD) is an X-linked lysosomal storage disorder caused by LAMP2 variants, with males presenting more severe phenotypes. However, evidence for genotype-phenotype correlation remains limit
Heart Lung Circ. 2026 Jan 19:S1443-9506(25)01622-1. doi: 10.1016/j.hlc.2025.08.026. Online ahead of print.ABSTRACTSerial two-dimensional transthoracic echocardiograms (TTE) are critical for accurate diagnosis, observation of disease progression and therapeutic response for patients with hypertrophic
Subcell Biochem. 2026;113:35-58. doi: 10.1007/978-3-032-05273-5_2.ABSTRACTStriated muscle is composed of overlapping arrays of thick myosin filaments and thin actin filaments. The thick filaments are composed of myosin molecules, which are hexamers of two heavy chains and two pairs of light chains.
Basic Res Cardiol. 2026 Jan 20. doi: 10.1007/s00395-025-01158-1. Online ahead of print.ABSTRACTAIMS: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and coronary microvascular dysfunction (CMD). The microRNA-144-3p (miR-144) has recently emer
Herz. 2026 Jan 20. doi: 10.1007/s00059-025-05359-1. Online ahead of print.ABSTRACTCardiac magnetic resonance imaging (CMR) provides decisive advantages, particularly in coronary heart disease, myocarditis and cardiomyopathy. It accurately detects ischemia, scarring, edema and microvascular disorders
No abstractJ Cardiothorac Surg. 2026 Jan 19. doi: 10.1186/s13019-025-03588-3. Online ahead of print.NO ABSTRACTPMID:41555403 | DOI:10.1186/s13019-025-03588-3
Pacing Clin Electrophysiol. 2026 Jan 19. doi: 10.1111/pace.70133. Online ahead of print.ABSTRACTBACKGROUND: The subcutaneous implantable cardioverter defibrillators (S-ICD) in hypertrophic cardiomyopathy (HCM) remains controversial. HCM patients are often younger and exposed to longer-term risks: co
Front Cardiovasc Med. 2026 Jan 2;12:1639855. doi: 10.3389/fcvm.2025.1639855. eCollection 2025.ABSTRACTAIMS: To provide real-world data on the symptomatic and hemodynamic response of the myosin inhibitor mavacamten in patients with hypertrophic obstructive cardiomyopathy (HOCM).METHODS: Patients with
Cureus. 2025 Dec 18;17(12):e99515. doi: 10.7759/cureus.99515. eCollection 2025 Dec.ABSTRACTApical sequestration is an often overlooked manifestation of mid-ventricular obstructive hypertrophic cardiomyopathy (MVO-HCM), in which dynamic mid-ventricular obstruction creates an anatomically and function
